Literature DB >> 4063137

The effect of etoposide on human CFU-GM.

R Bailey-Wood, C M Dallimore, T J Littlewood, D P Bentley.   

Abstract

Etoposide is being used increasingly in the treatment of a variety of malignant conditions and in conjunction with autologous bone marrow transplantation. We have examined the effect of the drug on human CFU-GM as an indication of the response of these bone marrow progenitor cells to measured plasma concentrations. When etoposide is present in the routine assay for 7 days, 50% growth of colony-forming CFU-GM occurs at a concentration of 0.0098 micrograms ml-1. When bovine serum albumin or human serum albumin is present this value is increased to 0.042 and 0.375 micrograms ml-1. Protein binding therefore plays an important part in modifying in vitro response and possibly in vivo response of these progenitor cells to etoposide.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4063137      PMCID: PMC1977245          DOI: 10.1038/bjc.1985.234

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  15 in total

1.  Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotixin glucopyranoside derivatives.

Authors:  L M Allen; P J Creaven
Journal:  Eur J Cancer       Date:  1975-10       Impact factor: 9.162

2.  Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.

Authors:  P A Radice; P A Bunn; D C Ihde
Journal:  Cancer Treat Rep       Date:  1979-08

3.  Inhibition by 4'-demethyl-epipodophyllotoxin 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside) of human lymphoblast cultures in G2 phase of the cell cycle.

Authors:  N C Misra; D W Roberts
Journal:  Cancer Res       Date:  1975-01       Impact factor: 12.701

4.  Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP16-213.

Authors:  G Rivera; T Avery; D W Roberts
Journal:  Eur J Cancer       Date:  1975-09       Impact factor: 9.162

5.  Effect of VP-16-213 on the intracellular degradation of DNA in HeLa cells.

Authors:  J D Loike; S B Horwitz
Journal:  Biochemistry       Date:  1976-12-14       Impact factor: 3.162

6.  VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules.

Authors:  F Cavalli; R W Sonntag; F Jungi; H J Senn; K W Brunner
Journal:  Cancer Treat Rep       Date:  1978-03

7.  4'-Demethyl-epipodophyllotoxin thenylidene glucoside (VM 26), a podophyllum compound with a new mechanism of action.

Authors:  H Stähelin
Journal:  Eur J Cancer       Date:  1970-08       Impact factor: 9.162

8.  Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer.

Authors:  W E Evans; J A Sinkule; W R Crom; L Dow; A T Look; G Rivera
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

9.  Anti-tumour activity of the epipodophyllin derivative VP16-213 (etoposide: NSC-141540) in gestational choriocarcinoma.

Authors:  E S Newlands; K D Bagshawe
Journal:  Eur J Cancer       Date:  1980-03       Impact factor: 9.162

10.  Effect of adriamycin on CFUGM at plasma concentrations found following therapeutic infusions.

Authors:  R Bailey-Wood; C M Dallimore; J A Whittaker
Journal:  Br J Cancer       Date:  1984-09       Impact factor: 7.640

View more
  3 in total

Review 1.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

2.  Disposition of total and unbound etoposide following high-dose therapy.

Authors:  T L Schwinghammer; R A Fleming; C S Rosenfeld; D Przepiorka; R K Shadduck; E J Bloom; C F Stewart
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 3.  The clinical pharmacology of etoposide and teniposide.

Authors:  P I Clark; M L Slevin
Journal:  Clin Pharmacokinet       Date:  1987-04       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.